Literature DB >> 12534940

Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16.

Vithagna Khammanivong1, Xiao Song Liu, Wen Jun Liu, Stuart J Rodda, Graham R Leggatt, Robert W Tindle, Ian H Frazer, Germain J P Fernando.   

Abstract

Many specific antiviral and antitumour immune responses have been attributed to the protective effects of antigen-specific CD8+ cytotoxic T lymphocytes (CTL). Recognition of virus infected or tumour cells by CTL requires presentation of at least one peptide epitope from a virus or tumour-specific antigen by the relevant MHC Class I molecule. Viral genes with mutations which remove CTL epitopes may thus be favoured for survival. Human cervical cancers are caused by papillomavirus infection, and these cancers consistently express the E7 protein of the oncogenic papillomavirus. We therefore investigated the MHC Class I restricted T cell epitopes of the human papillomavirus type 16 E7 oncoprotein using mice of five different genetic backgrounds, and an IFN-gamma ELISPOT assay, to determine the frequency with which MHC Class I epitopes might be expected in this small oncoprotein (98 amino acids). No MHC Class I restricted responses were detected in E7 immunized BALB/c (H-2d), CBA/CaH (H-2 k), FVB/N (H-2q) or A2KbH2b human HLA2.1 transgenic mice. In C57BL/6 J (H-2b) mice, a previously identified single antigenic epitope was detected. Therefore, we conclude that there is a paucity of MHC Class I restricted T cell epitopes in HPV16 E7 protein because of its small size. This might be advantageous to the virus. Furthermore here we present a quick and easy method to exhaustively determine CD8 T cell epitopes in proteins using a unique set of overlapping 8, 9 and 10 mer synthetic peptides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534940     DOI: 10.1046/j.1440-1711.2003.01130.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  10 in total

1.  Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7.

Authors:  Julie Ahn; Shiwen Peng; Chien-Fu Hung; Richard B S Roden; Tzyy-Choou Wu; Simon R Best
Journal:  Laryngoscope       Date:  2017-07-17       Impact factor: 3.325

2.  Immunogenic properties of recombinant and synthetic peptides of Human papillomavirus.

Authors:  R V Petrov; M R Khaitov; S M Andreev; S V Benevolenskii; O V Smirnova
Journal:  Dokl Biochem Biophys       Date:  2008 Jul-Aug       Impact factor: 0.788

3.  Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.

Authors:  John B Liao; Jean Publicover; John K Rose; Daniel DiMaio
Journal:  Clin Vaccine Immunol       Date:  2008-03-12

4.  Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses.

Authors:  Wenyi Gu; Melanie Cochrane; Graham R Leggatt; Elizabeth Payne; Allison Choyce; Fang Zhou; Robert Tindle; Nigel A J McMillan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-04       Impact factor: 11.205

5.  A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Authors:  Alberto Monroy-García; Miguel A Gómez-Lim; Benny Weiss-Steider; Georgina Paz-de la Rosa; Jorge Hernández-Montes; Karyna Pérez-Saldaña; Yessica S Tapia-Guerrero; Mariel E Toledo-Guzmán; Edelmiro Santiago-Osorio; Héctor I Sanchez-Peña; María de Lourdes Mora-García
Journal:  Virol J       Date:  2011-02-09       Impact factor: 4.099

6.  Investigation the Possibility of Using Peptides with a Helical Repeating Pattern of Hydro-Phobic and Hydrophilic Residues to Inhibit IL-10.

Authors:  Guoying Ni; Shu Chen; Yuedong Yang; Scott F Cummins; Jian Zhan; Zhixiu Li; Bin Zhu; Kate Mounsey; Shelley Walton; Ming Q Wei; Yuejian Wang; Yaoqi Zhou; Tianfang Wang; Xiaosong Liu
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 7.  Immunotherapy for HPV associated cancer.

Authors:  Ian H Frazer; Janin Chandra
Journal:  Papillomavirus Res       Date:  2019-07-13

8.  Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18.

Authors:  Kelly L Smith; Amanda Tristram; Kathleen M Gallagher; Alison N Fiander; Stephen Man
Journal:  Int Immunol       Date:  2004-12-27       Impact factor: 4.823

9.  Tumor targeting nanoparticle E749-57-HSP110-RGD elicits potent anti-tumor immune response in a CD8-dependent manner in cervical cancer-bearing mouse model.

Authors:  Yue Zhang; Faliang Ren; Bing Ni; Tao Jing; Jun Tang
Journal:  Hum Vaccin Immunother       Date:  2021-07-16       Impact factor: 4.526

10.  An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.

Authors:  Georgina Paz De la Rosa; Alberto Monroy-García; María de Lourdes Mora-García; Cristina Gehibie Reynaga Peña; Jorge Hernández-Montes; Benny Weiss-Steider; Miguel Angel Gómez-Lim
Journal:  Virol J       Date:  2009-01-06       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.